Edition:
United States

Edge Therapeutics Inc (EDGE.OQ)

EDGE.OQ on NASDAQ Stock Exchange Global Select Market

9.41USD
15 Dec 2017
Change (% chg)

$0.34 (+3.75%)
Prev Close
$9.07
Open
$9.07
Day's High
$9.47
Day's Low
$9.07
Volume
74,033
Avg. Vol
18,834
52-wk High
$13.37
52-wk Low
$7.44

Summary

Name Age Since Current Position

Sol Barer

69 2013 Independent Chairman of the Board

Brian Leuthner

52 President, Chief Executive Officer, Director

Isaac Blech

67 Independent Vice Chairman of the Board

Andrew Saik

48 2017 Chief Financial Officer

Daniel Brennan

49 2016 Chief Operating Officer

W. Bradford Middlekauff

55 2015 Senior Vice President, General Counsel, Secretary

Alyssa Wyant

42 2017 Senior Vice President, Regulatory Affairs

Albert Marchio

64 2017 Chief Accounting Officer, Chief Administrative Officer

R. Loch Macdonald

55 2009 Chief Scientific Officer, Director

Herbert Faleck

64 2013 Chief Medical Officer

Rosemary Crane

57 2017 Director

Kurt Conti

54 2010 Independent Director

James Healy

52 2015 Independent Director

James Loughlin

74 2011 Independent Director

Liam Ratcliffe

53 2016 Independent Director

Robert Spiegel

68 2013 Independent Director

Biographies

Name Description

Sol Barer

Dr. Sol J. Barer, Ph.D. is Independent Chairman of the Board of Edge Therapeutics, Inc. since September 2011 and has been Chairman of our board of directors and compensation committee since January 2013. He is the Managing Partner of SJ Barer Consulting and was a Chairman and CEO of Celgene Corporation. Dr. Barer spent 24 years at Celgene as, among other positions, President, COO and CEO, as well as its Executive Chairman and Chairman before retiring in June 2011. Dr. Barer served as Chairman of the Board of Cerecor, Inc., a biopharmaceutical company before retiring in April 2015. Dr. Barer currently serves as Chairman of the Board of ContraFect Corporation (NASDAQ: CFRX), a biotechnology company; Chairman of the Board of Medgenics, Inc. (NYSE: MDGN), a gene therapy company; Lead Independent Director of the Board of Restorgenex Corporation (OTC: RESX), a dermatological and ophthalmology and oncology medicine company, and Chairman of the Board of InspireMD, Inc. (NASDAQ: NSPR), a medical device company. He also is on the Board of Directors of Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Amicus Therapeutics, Inc. (NASDAQ: FOLD). Dr. Barer holds a B.S. from Brooklyn College. He earned his Ph.D. in Organic Chemistry from Rutgers University.

Brian Leuthner

Mr. Brian A. Leuthner is President, Chief Executive Officer, Director of Edge Therapeutics, Inc. He is one of our co-founders, has been our President and CEO since our inception in January 2009 and has also served on our board of directors since inception. He has more than 25 years of experience in the hospital acute care marketplace, with a specific expertise in critical care and neurocritical care. Prior to founding our company, Mr. Leuthner was the CEO of Fontus Pharmaceuticals, Inc. from 2007 to 2008, the Senior Head of Marketing for The Medicines Company (NASDAQ: MDCO) from 2005 to 2007 and the Director of Market Development for ESP Pharma, Inc. from 2003 to 2005. He also held marketing and sales positions of significant responsibility at Burroughs Wellcome and Company, Glaxo Wellcome plc and Johnson & Johnson (NYSE: JNJ). Mr. Leuthner received his B.S. and M.B.A. degrees from the University of North Carolina at Chapel Hill. Our board of directors believes Mr. Leuthner’s perspective and experience as our President and CEO, as well as his depth of operating and senior management experience in our industry and educational background, provide him with the qualifications and abilities to serve as a director.

Isaac Blech

Mr. Isaac Blech is Independent Vice Chairman of the Board of Edge Therapeutics, Inc. His current roles include Founder and Vice Chairman of Cerecor, Inc., a private company developing new treatments for central nervous system disorders, and Director of ContraFect Corporation (NASDAQ: CFRX), a public company developing therapies for infectious diseases. Since 2011, he has served as Vice Chairman of root9B Technologies, Inc. (OTC: RTNB), a public company working in the areas of financial regulations and cyber security, Vice Chairman of The SpendSmart Payments Company (OTC: SSPC), an electronic rewards company and Director of Medgenics, Inc. (NYSE: MDGN), a company creating new treatments for rare diseases. He is also Vice Chairman of Centrexion Corporation, a private company developing new modalities of pain control, Vice Chairman of Restorgenex Corporation, a specialty pharmaceutical company, Vice Chairman of WaveGuide Corporation, a company developing a portable NMR machine, Vice Chairman of Regenovation, Inc., a company developing new ways to regenerate human tissue and Vice Chairman of X-4 Pharmaceuticals, a cancer immunology company. Over the past 35 years, Mr. Blech has helped found several biotechnology companies, including Celgene Corporation (NASDAQ: CELG), ICOS Corporation, Pathogenesis Corporation, Nova Pharmaceutical Corporation and Genetic Systems Corporation. These companies are responsible for major advances in oncology, infectious disease and cystic fibrosis.

Andrew Saik

Mr. Andrew Saik is appointed as Chief Financial Officer of the company effective October 31, 2017. He most recently served as Chief Financial Officer of Vertice Pharma from November 2015 to July 2017. Mr. Saik served as Senior Vice President, Finance and Treasurer at Auxilium Pharmaceuticals Inc. (f/k/a Endo Health Solutions Inc.) (“Auxilium”) from August 2014 to January 2015, where he was responsible for internal and external reporting, global consolidations of M&A transactions, cash management, debt financing and risk management. During his tenure at Auxilium, he helped complete the $1.6 billion acquisition of Paladin Labs and refinance $3 billion in debt in a new corporate structure. Prior to Auxilium, Mr. Saik served in senior financial management roles with progressive responsibility at Valeant Pharmaceuticals International (f/k/a ICN Pharmaceuticals Inc.) (“Valeant”) from January 2001 to July 2002, most recently as its Senior Vice President, Finance. In this post, he served as the overall finance lead for the acquisition and integration of the Johnson & Johnson and Sanofi-Aventis dermatology business units in the U.S. and Canada, enabling Valeant to build the largest dermatology business in North America. Previously at Valeant, he was Chief Financial Officer of the $1.5 billion Specialty Pharmaceuticals Division which included the U.S., Canada and Australia. Earlier in his career, Mr. Saik was a finance manager and analyst at Nexgenix, Inc. from October 1999 to January 2001 and the Atlantic Richfield Corporation from June 1996 to October 1999. He holds a Master of Business Administration from the University of Southern California and a Bachelor of Arts from the University of California, Los Angeles.

Daniel Brennan

Mr. Daniel Brennan is Chief Operating Officer of the Company. Prior to being named Chief Operating Officer of Edge, Mr. Brennan served as Chief Operating Officer and Executive Vice President of Insys Therapeutics, Inc. since November 2015, where he was responsible for all commercial and general operating activities, including rebuilding the company’s commercial leadership team and practices. Prior to Insys, Mr. Brennan held multiple leadership positions at Lundbeck, Inc. (“Lundbeck”) from 2009 to 2015, including serving as Vice President and Group General Manager of the Neurology Business Unit and U.S. Business Development Group. Prior to Lundbeck, Mr. Brennan spent over a decade at Eli Lilly and Company in various sales, marketing and product development roles. Mr. Brennan received a B.A. from the University of Notre Dame and an M.B.A. degree, with distinction, from the Kellogg Graduate School of Business at Northwestern University.

W. Bradford Middlekauff

Mr. W. Bradford Middlekauff is Senior Vice President, General Counsel, Secretary of Edge Therapeutics, Inc. Most recently, Mr. Middlekauff served as Executive in Residence at Princeton University and as Chief Business Officer and General Counsel for Transparency Life Sciences, LLC. From 2008 to 2013, Mr. Middlekauff was Chief Legal Officer, General Counsel, and Secretary at Kolltan Pharmaceuticals, Inc., where he also ran the business development function. Prior to joining Kolltan, Mr. Middlekauff served as Senior Vice President, General Counsel and Secretary of Medarex, Inc. from 2000 to 2007 and Senior Vice President, Strategic Planning of Medarex from 2007 to 2008. Before Medarex, Mr. Middlekauff served as Vice President, Business Development and General Counsel at Algos Pharmaceuticals. Mr. Middlekauff began his legal career as an associate with the law firm of Cooley Godward LLP, where he advised life science companies on a broad range of business and legal matters. Mr. Middlekauff received an A.B. degree from Brown University and a J.D. degree from Yale Law School.

Alyssa Wyant

Ms. Alyssa J. S. Wyant is Senior Vice President, Regulatory Affairs of the Company. Ms. Wyant has nearly 20 years of global regulatory experience with a focus on the development, registration and successful launches of several innovative, biologic and small molecule orphan disease products. Most recently, Ms. Wyant served as Vice President, Global Regulatory Affairs at PTC from March 2015 to February 2017. While at PTC, she was responsible for the strategic planning and execution of global regulatory activities relating to several orphan disease indications and acted as regulatory agency liaison for a number of drug approval filings with the European Medicines Agency, FDA and Health Canada, among other significant regulatory responsibilities. Prior to her tenure at PTC, Ms. Wyant served as Senior Director, International Regulatory Affairs at NPS Pharmaceuticals from October 2012 to March 2015. Earlier in her career, she held multiple leadership positions in global regulatory affairs at Shire Human Genetic Therapies in the U.S. and Switzerland from January 2004 to October 2012. She also held regulatory affairs positions at Vertex Pharmaceuticals and Genetics Institute / Wyeth-Ayerst Pharmaceuticals. Ms. Wyant holds a B.S. in cell and molecular biology from the University of Washington.

Albert Marchio

Mr. Albert N. Marchio, II, is Chief Accounting Officer, Chief Administrative Officer Officer of the Company. He was Operations Officer of the Company. Prior to that, served as our Chief Financial Officer since December 2011. Mr. Marchio has more than 20 years of experience in the pharmaceutical industry. Prior to joining as our Chief Financial Officer, Mr. Marchio was a Managing Operating Partner with Three Fields Capital, a multi-strategy healthcare focused investment firm and provided consulting services to life science companies through Rockabye Valley Consulting from January 2009 to May 2013. Previously, Mr. Marchio served as the Executive Vice President, Chief Financial Officer of Informed Medical Communications from February 2008 to October 2009, and as the Vice President, Treasurer of MedPointe Pharmaceuticals from 2006 to January 2008. He began his career in life sciences as the Vice President, Treasurer of Alpharma, Inc. from 1992 to 2005. Mr. Marchio holds a B.A. in Economics from Muhlenberg College, an M.B.A. in Professional Accounting from Rutgers Graduate School of Business and a Post-M.B.A. Certificate in Taxation from Bernard Baruch College of the City University of New York.

R. Loch Macdonald

Dr. R. Loch Macdonald, M.D., Ph.D., is Chief Scientific Officer, Director of Edge Therapeutics, Inc. He is a scientist, researcher and neurosurgeon and a recognized expert on brain hemorrhage, including DCI. For the past 20 years, his research interest has focused on improving patient outcome after brain hemorrhage, with a specific focus on developing a cure for cerebral vasospasm and DCI. Since 2007, he has served as Keenan Endowed Chair, Head, Division of Neurosurgery at St. Michael’s Hospital and Professor of Neurosurgery at the University of Toronto. Prior to St. Michael’s Hospital, he was Professor of Surgery and Radiation & Cellular Oncology at the University Of Chicago Medical Center. Dr. Macdonald holds an M.D. from the University of British Columbia and a Ph.D. in Experimental Surgery from the University of Alberta. He completed his Neurosurgery residency at the University of Toronto.

Herbert Faleck

Dr. Herbert J. Faleck is Chief Medical Officer of the company. He is a pediatric neurologist trained at the Cleveland Clinic and has more than 25 years of extensive and successful experience in clinical research and development in the pharmaceutical and biotechnology industries. Prior to joining us, Dr. Faleck was with Celgene Corporation (NASDAQ: CELG) from 2000 to 2010. At Celgene, he served in several roles, most recently as the Chief Medical Officer for Celgene Cellular Therapeutics, where he led clinical, medical, regulatory and organizational development. He was also Celgene’s first Vice President of Clinical Research and Development. After leaving Celgene and prior to joining us in August 2013, Dr. Faleck was a freelance consultant. Previously, he held several positions at Novartis Pharmaceuticals Corporation. Dr. Faleck holds a D.O. from The University of Health Sciences College of Osteopathic Medicine.

Rosemary Crane

Ms. Rosemary A. Crane is Director of the company. She has served as President and Chief Executive Officer of MELA Sciences, Inc. from 2013 to 2014. Ms. Crane was Head of Commercialization and a partner at Appletree Partners from 2011 to 2013. From 2008 to 2011, she served as President and Chief Executive Officer of Epocrates Inc. Ms. Crane served in various senior and executive positions at Johnson & Johnson from 2002 to 2008, including as Group Chairman, OTC & Nutritional Group from 2006 to 2008, as Group Chairman Consumer, Specialty Pharmaceuticals and Nutritionals from 2004 to 2006, and as Executive Vice President of Global marketing for the Pharmaceutical Group from 2002 to 2004. Prior to that, she held various positions at Bristol Myers Squibb from 1982 to 2002, including as President of U.S. Primary Care from 2000 to 2002 and as President of Global Marketing and Consumer Products from 1998 to 2000. Ms. Crane has served as Vice Chairman of the board of Zealand Pharma A/S since 2015 and has served on the Board of Directors of Teva Pharmaceuticals since 2015. Ms. Crane received an M.B.A. from Kent State University in 1986 and a B.A. in communications and English from the State University of New York in 1981. She has over 32 years of experience in commercialization and business operations, primarily in the pharmaceutical and biotechnology industries, and more than 25 years of therapeutic and consumer drug launch expertise, as well as global experience.

Kurt Conti

Mr. Kurt G. Conti is Independent Director of Edge Therapeutics, Inc. Mr. Conti has been the CEO and President of the Conti Group since 1995. The Conti Group is a general contractor delivering program management, construction services, and engineering across the United States and internationally. In addition, Mr. Conti serves on executive boards and advisory committees such as the New York Building Congress, the Salvation Army, the Pingry School, and the Moles. Mr. Conti holds a B.S. in Civil Engineering from Villanova University and is a graduate of the Harvard University Business School Owner/President Management Program.

James Healy

Dr. James I. Healy, M.D. Ph.D. is Independent Director of the company. Dr. Healy has been a General Partner of Sofinnova Ventures, a venture capital firm, since June 2000. Prior to June 2000, Dr. Healy held various positions at Sanderling Ventures, Bayer Healthcare Pharmaceuticals (as successor to Miles Laboratories), Hyperion Therapeutics, Inc. (NASDAQ: HPTX) and ISTA Pharmaceuticals, Inc. Dr. Healy is currently on the board of directors of Ascendis Pharma A/S (NASDAQ: ASND), Auris Medical Holding AG (NASDAQ: EARS), Coherus BioSciences, Inc. (NASDAQ: CHRS), Amarin Corporation PLC (NASDAQ: AMRN), Natera, Inc. (NASDAQ: NTRA) and several private companies. Previously, he served as a board member of InterMune, Inc. (NASDAQ: ITMN), Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH), Durata Therapeutics, Inc. (NASDAQ: DRTX), CoTherix, Inc. (NASDAQ: CTRX), KaloBios Pharmaceuticals, Inc. (NASDAQ: KBIO) and several private companies. Dr. Healy holds an M.D. and a Ph.D. in Immunology from the Stanford School of Medicine and holds a B.A. in molecular biology and a B.A. in Scandinavian Studies from the University of California at Berkeley.

James Loughlin

Mr. James J. Loughlin is Independent Director of Edge Therapeutics, Inc. since November of 2011 and is the current chair of our audit committee. Since 2007, he has served on the board of Celgene Corporation (NASDAQ: CELG), where he has chaired the audit committee. Mr. Loughlin has also been a member of Celgene’s compensation committee since 2008. He is a member of the board and chair of the audit committee of InspireMD (NASDAQ: NSPR). Mr. Loughlin retired in 2003 after 40 years at KPMG LLP, a leading professional accounting and business consulting firm. As a partner at KPMG, he served for five years as a member of the board as well as National Director of the Pharmaceuticals Practice and as Chairman of the pension and investment committee of the KPMG Board from 1995 through 2001. Mr. Loughlin is a certified public accountant and received his B.S. degree in Accounting from St. Peter’s University in 1964.

Liam Ratcliffe

Dr. Liam T. Ratcliffe, M.D. Ph.D., is Independent Director of the Company. Dr. Ratcliffe is a Managing Director at New Leaf Venture Partners, and concentrates on biopharmaceutical investing. Dr. Ratcliffe joined New Leaf in September 2008. Dr. Ratcliffe was previously Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Additional positions during his 12 years at Pfizer included Vice President of Exploratory Development for the Mid West region (based in Ann Arbor, MI), and Head of Experimental Medicine at Pfizer’s Sandwich, UK Laboratories. Dr. Ratcliffe received his M.D. degree and Ph.D. degree in immunology from the University of Cape Town and his M.B.A. degree from the University of Michigan.

Robert Spiegel

Dr. Robert J. Spiegel, M.D. is Independent Director of the company. He has been an Associate Professor at Weill Cornell Medical College since 2012 and is an Advisor at Warburg Pincus, LLC. He also serves as Chief Medical Officer of PTC Therapeutics, Inc. (NASDAQ: PTCT). Prior to joining our board of directors, Dr. Spiegel spent more than 25 years at Schering-Plough Corporation where he was involved in clinical development, prior to retiring in 2009 from his position as Chief Medical Officer and Senior Vice President of the Schering-Plough Research Institute. Dr. Spiegel serves as a member of the board of directors of Geron Corporation (NASDAQ: GERN), a biotechnology oncology company, where he also serves on the compensation committee, and Avior Computing Corporation, a governance risk and compliance process technology company. He was previously a director of Talon Therapeutics, Inc. (formerly Hana Biosciences, Inc.), a biopharmaceutical oncology company, where he also served on the audit committee, and Clavis Pharma ASA, a pharmaceutical company based in Oslo, Norway. Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania. Following a residency in internal medicine, he completed a fellowship in medical oncology at the National Cancer Institute and held academic positions at the National Cancer Institute and New York University Cancer Center.